Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis
Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and...
Gespeichert in:
Veröffentlicht in: | Drug metabolism and disposition 2018-04, Vol.46 (4), p.429-439 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 439 |
---|---|
container_issue | 4 |
container_start_page | 429 |
container_title | Drug metabolism and disposition |
container_volume | 46 |
creator | Liu, Hong Stresser, David M. Michmerhuizen, Melissa J. Li, Xiaofeng Othman, Ahmed A. Reed, Aimee D. Schrimpf, Michael R. Sydor, Jens Lee, Anthony J. |
description | Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans. |
doi_str_mv | 10.1124/dmd.117.077511 |
format | Article |
fullrecord | <record><control><sourceid>proquest_elsev</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989606649</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090955624054370</els_id><sourcerecordid>2031736316</sourcerecordid><originalsourceid>FETCH-LOGICAL-e2201-13b505b9650917328cad326b7de12e127130dbe9b41535188afae82b11a8469d3</originalsourceid><addsrcrecordid>eNpdks1uEzEUhUcIJEJhy9oSGzZTfO35M7t0SlukpqCSSuxGHs-dxJFjp7YnIrwVL8LD8AQ4BDZIlu5ZfNfnyD5Z9hroOQAr3g3bIYn6nNZ1CfAkm0HJIKdUfH2azdKguSjL6nn2IoQNpVAUXMyyXwuMsndGhy2RdiCXOuxc0FE7S9xIJLlzezTkCxpUUe-R_PxRkzucvLPSkLnCeDBqnfYtkntUuIvOk_nKWR0imV8sc2AV0ZbcTFtpw3vSrqWXKqLX3-U_k7hGspCbtHjvDAYyJnVl5F7bvHU2Sm21XZGFs859O6zQypCgY9iHy8_5tZnUMY0LB0OWPpmM6BNBYF78gdgF0GOCVkZpDkGHl9mzUZqAr_7Os-zh6sOyvclvP11_bOe3OTJGIQfel7TsRVVSATVnjZIDZ1VfDwgsnRo4HXoUfQElL6Fp5CixYT2AbIpKDPwse3u6d-fd44QhdlsdFBojLbopdCAaUdGqKkRC3_yHbtzk0wuHjlGe3CsOVaKaE4Up9V6j74LSaBUO2qff6QanO6DdsQxdKkMSdXcqA_8Nu6KqpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2031736316</pqid></control><display><type>article</type><title>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Liu, Hong ; Stresser, David M. ; Michmerhuizen, Melissa J. ; Li, Xiaofeng ; Othman, Ahmed A. ; Reed, Aimee D. ; Schrimpf, Michael R. ; Sydor, Jens ; Lee, Anthony J.</creator><creatorcontrib>Liu, Hong ; Stresser, David M. ; Michmerhuizen, Melissa J. ; Li, Xiaofeng ; Othman, Ahmed A. ; Reed, Aimee D. ; Schrimpf, Michael R. ; Sydor, Jens ; Lee, Anthony J.</creatorcontrib><description>Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.</description><identifier>ISSN: 0090-9556</identifier><identifier>EISSN: 1521-009X</identifier><identifier>DOI: 10.1124/dmd.117.077511</identifier><language>eng</language><publisher>Bethesda: Elsevier Inc</publisher><subject>Catalysis ; Dimethylaniline monooxygenase (N-oxide-forming) ; Drug dosages ; Excretion ; Feces ; Flavin ; Glucuronosyltransferase ; Hepatocytes ; Kidneys ; Liver ; Metabolism ; Metabolites ; Monkeys ; Oxidation ; Pharmacology ; Radioactivity ; Uridine ; Urine</subject><ispartof>Drug metabolism and disposition, 2018-04, Vol.46 (4), p.429-439</ispartof><rights>2018 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright Lippincott Williams & Wilkins Ovid Technologies Apr 1, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Stresser, David M.</creatorcontrib><creatorcontrib>Michmerhuizen, Melissa J.</creatorcontrib><creatorcontrib>Li, Xiaofeng</creatorcontrib><creatorcontrib>Othman, Ahmed A.</creatorcontrib><creatorcontrib>Reed, Aimee D.</creatorcontrib><creatorcontrib>Schrimpf, Michael R.</creatorcontrib><creatorcontrib>Sydor, Jens</creatorcontrib><creatorcontrib>Lee, Anthony J.</creatorcontrib><title>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</title><title>Drug metabolism and disposition</title><description>Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.</description><subject>Catalysis</subject><subject>Dimethylaniline monooxygenase (N-oxide-forming)</subject><subject>Drug dosages</subject><subject>Excretion</subject><subject>Feces</subject><subject>Flavin</subject><subject>Glucuronosyltransferase</subject><subject>Hepatocytes</subject><subject>Kidneys</subject><subject>Liver</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Monkeys</subject><subject>Oxidation</subject><subject>Pharmacology</subject><subject>Radioactivity</subject><subject>Uridine</subject><subject>Urine</subject><issn>0090-9556</issn><issn>1521-009X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdks1uEzEUhUcIJEJhy9oSGzZTfO35M7t0SlukpqCSSuxGHs-dxJFjp7YnIrwVL8LD8AQ4BDZIlu5ZfNfnyD5Z9hroOQAr3g3bIYn6nNZ1CfAkm0HJIKdUfH2azdKguSjL6nn2IoQNpVAUXMyyXwuMsndGhy2RdiCXOuxc0FE7S9xIJLlzezTkCxpUUe-R_PxRkzucvLPSkLnCeDBqnfYtkntUuIvOk_nKWR0imV8sc2AV0ZbcTFtpw3vSrqWXKqLX3-U_k7hGspCbtHjvDAYyJnVl5F7bvHU2Sm21XZGFs859O6zQypCgY9iHy8_5tZnUMY0LB0OWPpmM6BNBYF78gdgF0GOCVkZpDkGHl9mzUZqAr_7Os-zh6sOyvclvP11_bOe3OTJGIQfel7TsRVVSATVnjZIDZ1VfDwgsnRo4HXoUfQElL6Fp5CixYT2AbIpKDPwse3u6d-fd44QhdlsdFBojLbopdCAaUdGqKkRC3_yHbtzk0wuHjlGe3CsOVaKaE4Up9V6j74LSaBUO2qff6QanO6DdsQxdKkMSdXcqA_8Nu6KqpQ</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Liu, Hong</creator><creator>Stresser, David M.</creator><creator>Michmerhuizen, Melissa J.</creator><creator>Li, Xiaofeng</creator><creator>Othman, Ahmed A.</creator><creator>Reed, Aimee D.</creator><creator>Schrimpf, Michael R.</creator><creator>Sydor, Jens</creator><creator>Lee, Anthony J.</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics, Inc</general><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</title><author>Liu, Hong ; Stresser, David M. ; Michmerhuizen, Melissa J. ; Li, Xiaofeng ; Othman, Ahmed A. ; Reed, Aimee D. ; Schrimpf, Michael R. ; Sydor, Jens ; Lee, Anthony J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e2201-13b505b9650917328cad326b7de12e127130dbe9b41535188afae82b11a8469d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Catalysis</topic><topic>Dimethylaniline monooxygenase (N-oxide-forming)</topic><topic>Drug dosages</topic><topic>Excretion</topic><topic>Feces</topic><topic>Flavin</topic><topic>Glucuronosyltransferase</topic><topic>Hepatocytes</topic><topic>Kidneys</topic><topic>Liver</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Monkeys</topic><topic>Oxidation</topic><topic>Pharmacology</topic><topic>Radioactivity</topic><topic>Uridine</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Stresser, David M.</creatorcontrib><creatorcontrib>Michmerhuizen, Melissa J.</creatorcontrib><creatorcontrib>Li, Xiaofeng</creatorcontrib><creatorcontrib>Othman, Ahmed A.</creatorcontrib><creatorcontrib>Reed, Aimee D.</creatorcontrib><creatorcontrib>Schrimpf, Michael R.</creatorcontrib><creatorcontrib>Sydor, Jens</creatorcontrib><creatorcontrib>Lee, Anthony J.</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Drug metabolism and disposition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Hong</au><au>Stresser, David M.</au><au>Michmerhuizen, Melissa J.</au><au>Li, Xiaofeng</au><au>Othman, Ahmed A.</au><au>Reed, Aimee D.</au><au>Schrimpf, Michael R.</au><au>Sydor, Jens</au><au>Lee, Anthony J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</atitle><jtitle>Drug metabolism and disposition</jtitle><date>2018-04</date><risdate>2018</risdate><volume>46</volume><issue>4</issue><spage>429</spage><epage>439</epage><pages>429-439</pages><issn>0090-9556</issn><eissn>1521-009X</eissn><abstract>Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.</abstract><cop>Bethesda</cop><pub>Elsevier Inc</pub><doi>10.1124/dmd.117.077511</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-9556 |
ispartof | Drug metabolism and disposition, 2018-04, Vol.46 (4), p.429-439 |
issn | 0090-9556 1521-009X |
language | eng |
recordid | cdi_proquest_miscellaneous_1989606649 |
source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Catalysis Dimethylaniline monooxygenase (N-oxide-forming) Drug dosages Excretion Feces Flavin Glucuronosyltransferase Hepatocytes Kidneys Liver Metabolism Metabolites Monkeys Oxidation Pharmacology Radioactivity Uridine Urine |
title | Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_elsev&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolism%20and%20Disposition%20of%20a%20Novel%20Selective%20%CE%B17%20Neuronal%20Acetylcholine%20Receptor%20Agonist%20ABT-126%20in%20Humans:%20Characterization%20of%20the%20Major%20Roles%20for%20Flavin-Containing%20Monooxygenases%20and%20UDP-Glucuronosyl%20Transferase%201A4%20and%202B10%20in%20Catalysis&rft.jtitle=Drug%20metabolism%20and%20disposition&rft.au=Liu,%20Hong&rft.date=2018-04&rft.volume=46&rft.issue=4&rft.spage=429&rft.epage=439&rft.pages=429-439&rft.issn=0090-9556&rft.eissn=1521-009X&rft_id=info:doi/10.1124/dmd.117.077511&rft_dat=%3Cproquest_elsev%3E2031736316%3C/proquest_elsev%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2031736316&rft_id=info:pmid/&rft_els_id=S0090955624054370&rfr_iscdi=true |